HALO

Halozyme Therapeutics (HALO)

About Halozyme Therapeutics (HALO)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Details

Daily high

$48.20

Daily low

$46.88

Price at open

$47.03

52 Week High

$65.53

52 Week Low

$33.15

Market cap

6.0B

Dividend yield

0.00%

Volume

4.8M

Avg. volume

1.5M

P/E ratio

15.54

Halozyme Therapeutics News